Trends in neoadjuvant chemotherapy use and oncological outcomes for muscle-invasive bladder cancer in Japan: a multicenter study | Zendy

Go Anan | Zendy; Shingo Hatakeyama | Zendy; Naoki Fujita | Zendy; Hiromichi Iwamura | Zendy; Toshikazu Tanaka | Zendy; Hayato Yamamoto | Zendy; Yuki Tobisawa | Zendy; T. Yoneyama | Zendy; Takahiro Yoneyama | Zendy; Yasuhiro Hashimoto | Zendy; Takuya Koie | Zendy; Hiroyuki Ito | Zendy; Kunio Yoshikawa | Zendy; Toshiaki Kawaguchi | Zendy; Makoto Sato | Zendy; Chikara Οhyama | Zendy

Open Access

Trends in neoadjuvant chemotherapy use and oncological outcomes for muscle-invasive bladder cancer in Japan: a multicenter study

Author(s) -

Go Anan,

Shingo Hatakeyama,

Naoki Fujita,

Hiromichi Iwamura,

Toshikazu Tanaka,

Hayato Yamamoto,

Yuki Tobisawa,

T. Yoneyama,

Takahiro Yoneyama,

Yasuhiro Hashimoto,

Takuya Koie,

Hiroyuki Ito,

Kunio Yoshikawa,

Toshiaki Kawaguchi,

Makoto Sato,

Chikara Οhyama

Publication year - 2017

Publication title -

oncotarget

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.373

H-Index - 127

ISSN - 1949-2553

DOI - 10.18632/oncotarget.20991

Subject(s) - carboplatin , medicine , bladder cancer , cystectomy , cisplatin , oncology , proportional hazards model , chemotherapy , nomogram , neoadjuvant therapy , cancer , urology , breast cancer

Despite benefits of neoadjuvant chemotherapy (NAC), the adoption of guideline recommendations for NAC use in patients with muscle-invasive bladder cancer (MIBC) has been slow. We aimed to evaluate temporal trends in NAC use and oncological outcomes in a representative cohort of patients with MIBC.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Empowering knowledge with every search

About

About Careers Publisher Partners Contact Us

Learn

FAQs Blog Terms of Use Privacy Policy

About

Learn

Discover

Explore